Diagnosis and Management of Cerebral Vasospasm Following Aneurysmal SAH
Abstract
Cerebral Vasospasm, characterized by the progressive constriction of cerebral arteries, often occurs following a subarachnoid hemorrhage (SAH) and is a leading cause of morbidity and mortality in affected patients. This condition can be resulted in cerebral ischemia, the severity of which correlates with the degree of vasospasm. The underlying pathophysiology involves the encasement of arteries by blood clots, although the intricate interactions between the hematoma and adjacent structures remain incompletely understood. The delayed onset of vasospasm offers a potential window for preventive interventions. However, recent randomized controlled trials have been discouraging, as they failed to demonstrate any significant improvement in patient outcomes with the use of clazosentan (an endothelin antagonist), simvastatin (a cholesterol-lowering agent), or magnesium sulfate (a vasodilator). Current best practices for managing vasospasm include minimizing ischemia by maintaining adequate blood volume and pressure, administering nimodipine (a calcium channel blocker), and, when necessary, performing balloon angioplasty. Over the past two decades, advancements in the management of vasospasm have significantly reduced associated morbidity and mortality rates. Nevertheless, vasospasm remains a critical determinant of clinical outcomes following aneurysmal rupture.
Keywords
Full Text:
PDFReferences
Lominadze G, Lessen S, Keene A. Vasospasm risk in surgical ICU patients with grade I subarachnoid hemorrhage. Neurohospitalist. 2016 Jan;6(1):20–3.
Romenskaya T, Longhitano Y, Piccolella F, Berger JM, Artico M, Taurone S, et al. Cerebral vasospasm: practical review of diagnosis and management. RRCT. 2023 Feb;18(1):12–8.
Aoki T, Frȍsen J, Fukuda M, Bando K, Shioi G, Tsuji K, et al. Prostaglandin E2 –EP2–NF-κB signaling in macrophages as a potential therapeutic target for intracranial aneurysms. Sci Signal. 2017 Feb 7;10(465):eaah6037.
D’Souza S. Aneurysmal subarachnoid hemorrhage. J Neurosurg Anesthesiol. 2015 July;27(3):222–40.
Viderman D, Tapinova K, Abdildin YG. Mechanisms of cerebral vasospasm and cerebral ischaemia in subarachnoid haemorrhage. Clin Physio Funct Imaging. 2023 Jan;43(1):1–9.
Romoli M, Giammello F, Mosconi MG, De Mase A, De Marco G, Digiovanni A, et al. Immunological profile of vasospasm after subarachnoid hemorrhage. IJMS. 2023 May 16;24(10):8856.
Zangi M, Asadi AM, Amirdosara M, Mokhtari M, Goharani R, Sanei MS, et al. Enhanced recovery after surgery (ERAS) protocol for craniotomy patients: a systematic review. Anesth Pain Med. 2024 Oct;14(5):e146811.
Deshaies EM, Boulos AS, Drazin D, Popp AJ. Evidence-based pharmacotherapy for cerebral vasospasm. Neurological Research. 2009 July;31(6):615–20.
Hasegawa S, Hasegawa Y, Miura M. Current therapeutic drugs against cerebral vasospasm after subarachnoid hemorrhage: a comprehensive review of basic and clinical studies. CDD [Internet]. 2017 Sept 6 [cited 2025 Sept 22];14(6). Available from: http://www.eurekaselect.com/144587/article
Siasios I, Kapsalaki EZ, Fountas KN. Cerebral vasospasm pharmacological treatment: an update. Neurolog Res Int. 2013;2013:1–20.
Ciurea AV, Palade C, Voinescu D, Nica DA. Subarachnoid hemorrhage and cerebral vasospasm - literature review. J Med Life. 2013 June 15;6(2):120–5.
Harrod CG, Bendok BR, Batjer HH. Prediction of cerebral vasospasm in patients presenting with aneurysmal subarachnoid hemorrhage: a review. Neurosurgery. 2005 Apr 1;56(4):633–54.
Chan AY, Choi EH, Yuki I, Suzuki S, Golshani K, Chen JW, et al. Cerebral vasospasm after subarachnoid hemorrhage: developing treatments. Brain Hemorrhages. 2021 Mar;2(1):15–23.
Carr KR, Zuckerman SL, Mocco J. Inflammation, cerebral vasospasm, and evolving theories of delayed cerebral ischemia. Neurol Res Int. 2013;2013:506584.
Wojak JC, Abruzzo TA, Bello JA, Blackham KA, Hirsch JA, Jayaraman MV, et al. Quality improvement guidelines for adult diagnostic cervicocerebral angiography: update cooperative study between the Society of Interventional Radiology (SIR), American Society of Neuroradiology (ASNR), and Society of NeuroInterventional Surgery (SNIS). J Vasc Inter Radiolog. 2015 Nov;26(11):1596–608.
Macdonald RL. Origins of the concept of vasospasm. Stroke [Internet]. 2016 Jan [cited 2025 Sept 23];47(1). Available from: https://www.ahajournals.org/doi/10.1161/STROKEAHA.114.006498
Inagawa T, Yahara K, Ohbayashi N. Risk factors associated with cerebral vasospasm following aneurysmal subarachnoid hemorrhage. Neurol Med Chir (Tokyo). 2014 June 17;54(6):465–73.
Rumalla K, Lin M, Ding L, Gaddis M, Giannotta SL, Attenello FJ, et al. Risk factors for cerebral vasospasm in aneurysmal subarachnoid hemorrhage: a population-based study of 8346 patients. World Neurosurgery. 2021;145:e233–41.
Baggott CD, Aagaard-Kienitz B. Cerebral vasospasm. Neurosurgery Clinics of North America. 2014 July;25(3):497–528.
Schneider UC, Xu R, Vajkoczy P. Inflammatory events following subarachnoid hemorrhage (SAH). CN. 2018;16(9):1385–95.
DOI: https://doi.org/10.24244/jni.v14i3.657
Refbacks
- There are currently no refbacks.

JNIis licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License